



Article Type: Review Article

Available online: www.ujmrst.twistingmemoirs.com

FLUOROQUINOLONE: A NEW FRONTIER IN ANTIBACTERIAL DRUG DEVELOPMENT

Pushpendra Panwar¹, Shivangni Rathore^{2*}, Revathi A Gupta³

Institute of Pharmacy, Dr. A.P.J. Abdul Kalam University, Indore, Madhya Pradesh, India

Corresponding Author: Shivangni Rathore Email: srathore990@gmail.com

ABSTRACT

Fluoroquinolones (FQs) have emerged as a crucial class of synthetic antibacterial agents with broad-spectrum activity and versatile clinical applications. This review aims to explore their historical evolution, structural modifications, mechanism of action, clinical utility, and recent advancements in the context of rising antimicrobial resistance. A comprehensive literature survey was conducted using scientific databases including PubMed, ScienceDirect, and Google Scholar. Studies on fluoroquinolone pharmacodynamics, structure–activity relationships (SAR), resistance mechanisms, and novel derivatives were critically analysed. FQs exert bactericidal effects by targeting bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication and transcription. Successive generations of FQs show improved activity, pharmacokinetics, and reduced toxicity. Structural modifications at specific positions (C-6, C-7, and C-8) have led to enhanced potency and spectrum. Despite their success, resistance via mutations and efflux mechanisms poses significant challenges. Recent innovations such as delafloxacin and finafloxacin, and nanocarrier-based delivery systems, offer new avenues for overcoming these limitations. Fluoroquinolones continue to be vital in the antibacterial arsenal, especially against drug-resistant infections. Their rational development, guided by SAR and molecular modelling, holds promise for future therapies. However, preserving their efficacy necessitates judicious clinical use and ongoing research into safer, more effective derivatives.

Keywords: Fluoroquinolones, Antibacterial resistance, DNA gyrase, Structure–activity relationship, Topoisomerase inhibition, Novel derivatives

INTRODUCTION

The global burden of infectious diseases continues to pose a serious public health challenge, especially in the face of rising antimicrobial resistance (AMR). Among the various classes of antibiotics developed over the past century, fluoroquinolones (FQs) have emerged as a vital component in the fight against bacterial infections. Representing a significant evolution from

the original quinolone nucleus, fluoroquinolones have demonstrated remarkable broad-spectrum antibacterial activity, targeting both Gram-positive and Gram-negative pathogens [1]. Their unique mechanism of action, high oral bioavailability, and favourable pharmacokinetic profiles have made them indispensable in both hospital and community settings. Fluoroquinolones are synthetic chemotherapeutic agents derived from nalidixic acid, the first quinolone introduced in the 1960s for the treatment of urinary tract infections. Subsequent modifications, particularly the incorporation of a fluorine atom at position C6 and other strategic substitutions at positions N1, C7, and C8 of the quinolone core, have dramatically enhanced their potency, expanded their antimicrobial spectrum, and improved their pharmacological properties. This led to the classification of fluoroquinolones into generations, with newer generations exhibiting improved activity against resistant organisms and better tissue penetration [2].

The mechanism of action of fluoroquinolones is distinct and involves the inhibition of bacterial DNA gyrase and topoisomerase IV, enzymes crucial for DNA replication, transcription, and repair. This dual-targeting mechanism not only contributes to their efficacy but also helps reduce the rate of resistance development compared to antibiotics with a single molecular target [3]. However, the clinical utility of fluoroquinolones has been increasingly threatened by the emergence of resistance, largely due to mutations in target enzymes, efflux pump overexpression, and plasmid-mediated resistance genes such as *qnr*, *aac* (6')-Ib-cr, and *qepA*. Despite the challenges posed by resistance, fluoroquinolones remain one of the most commonly prescribed antibiotic classes, with applications ranging from respiratory tract infections and gastrointestinal diseases to complicated urinary tract infections and multidrug-resistant tuberculosis. Moreover, ongoing structural optimization has led to the development of newer fluoroquinolones with improved safety profiles and activity against resistant strains. Compounds such as delafloxacin, finafloxacin, and zabofloxacin exemplify recent advances in this domain, offering renewed hope for the management of difficult-to-treat infections [4]. Given the evolving landscape of antibacterial therapy, the continued exploration of fluoroquinolones as a therapeutic class holds promise. Research efforts are currently focused on developing next-generation fluoroquinolones with enhanced specificity, minimized toxicity, and resistance-bypassing mechanisms. Additionally, their potential in combination therapies, novel drug delivery systems, and niche applications like intracellular pathogens and biofilm-associated infections are being actively investigated.

This review aims to provide a comprehensive overview of fluoroquinolones, tracing their historical development, elucidating their mode of action, and discussing their clinical relevance and limitations. It also highlights recent advancements and future directions, positioning fluoroquinolones as a dynamic and evolving frontier in antibacterial drug development [5].

Historical Evolution of Fluoroquinolones

The history of fluoroquinolones begins with the discovery of nalidixic acid in 1962, a by-product during the synthesis of the antimalarial drug chloroquine. Although nalidixic acid was effective in treating urinary tract infections caused by Gram-negative bacteria, it suffered from poor systemic bioavailability and a narrow spectrum of activity. This prompted efforts to improve its antimicrobial profile through structural modifications [6]. The major breakthrough came in the 1980s with the introduction of the first true fluoroquinolone, norfloxacin, which featured a fluorine atom at the C6 position. This structural change enhanced cell wall penetration and broadened antimicrobial activity. The addition of a piperazine ring at C7 further improved potency and pharmacokinetics, laying the foundation for a new class of antibacterial agents.

Subsequent decades witnessed the development of second-generation fluoroquinolones such as ciprofloxacin and ofloxacin, which demonstrated improved systemic distribution and

efficacy against a broader spectrum of bacteria. Third-generation agents like levofloxacin and sparfloxacin exhibited enhanced activity against Gram-positive organisms and atypical pathogens [7]. The fourth generation, including moxifloxacin and gatifloxacin, was designed to target both DNA gyrase and topoisomerase IV effectively, reducing the likelihood of resistance development.

The evolution of fluoroquinolones reflects a successful example of rational drug design in antibacterial therapy. Each generation has addressed previous limitations, enhancing antimicrobial potency, safety, and pharmacokinetics [8]. Ongoing research continues to explore newer derivatives with the goal of overcoming resistance and expanding clinical utility, marking fluoroquinolones as a dynamic and adaptable class of antibiotics.

Mechanism of Action

Fluoroquinolones exert their bactericidal activity by targeting two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV, both of which are critical for DNA replication, transcription, recombination, and repair. These enzymes are classified as type II topoisomerases and are responsible for managing DNA topology during cellular processes [9]. In Gram-negative bacteria, DNA gyrase is the primary target. It introduces negative supercoils into circular DNA, which is necessary for DNA condensation and accessibility. Fluoroquinolones bind to the DNA–enzyme complex, stabilizing it and preventing the resealing of the DNA strands after cleavage. This results in double-stranded DNA breaks and the inhibition of vital cellular functions, ultimately leading to cell death.

In contrast, topoisomerase IV is the preferred target in Gram-positive bacteria. This enzyme plays a key role in decatenation, or the separation of interlinked daughter chromosomes following DNA replication. By inhibiting topoisomerase IV, fluoroquinolones prevent proper chromosome segregation during cell division, which is lethal to the bacterial cell [10-12].

The action of fluoroquinolones is concentration-dependent, with a rapid onset of bactericidal activity. Their ability to inhibit two separate but related enzymes provide a dual mechanism of action, which not only enhances their effectiveness but also reduces the likelihood of resistance development through single-point mutations.

The unique mechanism of fluoroquinolones, distinct from other classes such as β -lactams or macrolides, makes them valuable in treating infections caused by multidrug-resistant organisms. However, improper use can still lead to resistance, underscoring the importance of judicious prescription [13].

Spectrum of Antibacterial Activity

Fluoroquinolones possess a broad-spectrum antibacterial profile, making them effective against a wide range of Gram-negative, Gram-positive, atypical, and intracellular pathogens. Their spectrum of activity has expanded significantly with successive generations, allowing them to be used in diverse clinical settings [14-16].

a) Gram-Negative Bacteria

Fluoroquinolones are highly effective against many Gram-negative organisms, particularly *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus spp.*, *Salmonella*, *Shigella*, *Pseudomonas aeruginosa*, and *Neisseria gonorrhoeae*. Ciprofloxacin and levofloxacin are commonly used to treat infections caused by these organisms, including urinary tract infections, gastroenteritis, and some hospital-acquired infections.

b) Gram-Positive Bacteria

Later generations of fluoroquinolones, such as levofloxacin and moxifloxacin, show enhanced activity against Gram-positive pathogens, including *Streptococcus pneumoniae*,

Staphylococcus aureus (including MSSA), and *Enterococcus faecalis*. However, their activity against MRSA is generally limited and varies by compound and region.

c) Atypical and Intracellular Pathogens

Fluoroquinolones are particularly valuable in treating infections caused by atypical organisms such as *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Legionella pneumophila*, due to their excellent intracellular penetration and activity. This makes them effective in managing atypical community-acquired pneumonia and sexually transmitted infections.

d) Mycobacteria and Others

Newer fluoroquinolones like moxifloxacin and gatifloxacin exhibit activity against *Mycobacterium tuberculosis*, making them promising agents in the treatment of drug-resistant tuberculosis. They also show activity against *Bacillus anthracis*, contributing to their role in post-exposure prophylaxis for anthrax [17-18].

Structural Modifications and Generations

Fluoroquinolones are derived from the 1,4-dihydroquinoline-3-carboxylic acid scaffold, with antibacterial activity highly dependent on substitutions at specific positions of the core ring. Strategic modifications have led to improvements in potency, spectrum, pharmacokinetics, and safety. The carboxylic acid at C3 and the keto group at C4 are essential for chelating magnesium ions that mediate binding to DNA gyrase and topoisomerase IV. These groups are crucial for activity and remain conserved across all fluoroquinolones [19-21]. The addition of a fluorine atom at C6 significantly enhances lipophilicity, improving cell wall penetration and increasing activity against both Gram-negative and Gram-positive bacteria. This substitution is the hallmark of fluoroquinolones [20].

The N1 position modulates potency and spectrum. A cyclopropyl group (e.g., in ciprofloxacin) increases activity against Gram-negative bacteria and *Mycobacterium tuberculosis*. Larger or bulkier groups may impair binding or limit penetration [21]. Substituents at C7, often piperazine or related heterocycles, enhance affinity for DNA gyrase and influence activity against Gram-negative organisms. However, they can increase CNS side effects due to GABA receptor antagonism. The C8 position affects phototoxicity and anaerobic activity. A methoxy group (as in moxifloxacin) reduces phototoxic potential and improves activity against anaerobes and some resistant strains. Minor modifications at C5 can alter pharmacokinetic or safety profiles, though this position is less critical for antibacterial action. Understanding SAR allows the rational design of newer fluoroquinolones with improved efficacy, reduced resistance potential, and better safety profiles for clinical use [22-24].

Pharmacokinetics and Pharmacodynamics

Fluoroquinolones exhibit favourable pharmacokinetic (PK) and pharmacodynamic (PD) profiles, contributing to their wide therapeutic application. Most fluoroquinolones have high oral bioavailability (ranging from 70–100%), allowing effective oral and intravenous formulations. Peak plasma concentrations are typically reached within 1–2 hours of oral dosing, and food has minimal impact on absorption, though chelation with divalent or trivalent cations (e.g., calcium, magnesium, iron) can reduce bioavailability [25-27]. The volume of distribution (Vd) is generally large, enabling good tissue penetration, particularly into the lungs, urinary tract, gastrointestinal mucosa, and intracellular compartments. This makes fluoroquinolones effective for respiratory, urinary, and systemic infections. Many agents, including levofloxacin and moxifloxacin, also cross the blood–brain barrier to some extent [28]. Elimination pathways vary: some fluoroquinolones (e.g., ciprofloxacin, levofloxacin) are primarily renally excreted, making them suitable for urinary tract infections, while others like moxifloxacin undergo hepatic metabolism, offering benefits in patients with renal impairment.

Pharmacodynamically, fluoroquinolones exhibit concentration-dependent killing, meaning efficacy correlates with the peak drug concentration (C_{max}) or the area under the concentration–time curve (AUC) relative to the minimum inhibitory concentration (MIC). The most predictive parameter is the AUC/MIC ratio, with targets varying by pathogen and infection site [29]. Their post-antibiotic effect (PAE), where bacterial growth remains suppressed after drug levels fall below MIC, further enhances therapeutic efficacy and supports once- or twice-daily dosing regimens.

Clinical Applications

Fluoroquinolones are widely used due to their broad-spectrum activity, excellent tissue penetration, and oral bioavailability. They are effective in treating a variety of infections across both community and hospital settings [30–32]. In respiratory tract infections, newer fluoroquinolones like levofloxacin and moxifloxacin are commonly used for community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis, and sinusitis due to their enhanced activity against *Streptococcus pneumoniae* and atypical pathogens [33]. In urinary tract infections (UTIs), ciprofloxacin and levofloxacin are effective for both uncomplicated and complicated cases, including pyelonephritis and prostatitis. Ciprofloxacin is also a first-line agent for gastrointestinal infections like infectious diarrhoea and typhoid fever. Fluoroquinolones play a role in bone and joint infections, skin and soft tissue infections, and intra-abdominal infections, especially when caused by resistant Gram-negative organisms [34]. They are also important in tuberculosis (TB) management, particularly multidrug-resistant TB (MDR-TB), where moxifloxacin and levofloxacin are key second-line agents. In prophylaxis, fluoroquinolones are used in neutropenic cancer patients and in post-exposure prevention of anthrax and meningococcal infections [35]. Despite their utility, fluoroquinolone use should be judicious to avoid resistance and adverse effects. Clinical guidelines now recommend limiting their use to cases where safer alternatives are unavailable.

Recent Advances and Novel Derivatives

In response to rising resistance and safety concerns, recent research has focused on developing next-generation fluoroquinolones and optimizing their use through molecular modifications, novel delivery systems, and combination therapies [36].

➤ Novel Fluoroquinolone Derivatives

Newer agents such as delafloxacin, finafloxacin, and zabofloxacin represent significant advances:

- Delafloxacin is an anionic fluoroquinolone with enhanced activity in acidic environments such as abscesses and intracellular spaces. It exhibits potent activity against MRSA, Gram-negative bacilli, and atypical pathogens, making it suitable for acute bacterial skin and skin structure infections (ABSSSIs) and respiratory infections.
- Finafloxacin demonstrates increased antibacterial efficacy at low pH and is being explored for otitis externa and urinary tract infections, especially where standard fluoroquinolones fail [37].
- Zabofloxacin has improved Gram-positive activity and is under investigation for respiratory infections.

➤ Hybrid and Dual-Targeting Molecules

Some derivatives are designed to simultaneously inhibit DNA gyrase and topoisomerase IV with high affinity, reducing resistance potential. Structural modifications at C7 and C8 aim to increase selectivity, reduce toxicity, and improve activity against resistant strains [38].

➤ **Nanotechnology and Drug Delivery**

Nanoformulations, including liposomal and polymeric nanoparticles, are being studied to improve solubility, targeted delivery, and intracellular penetration, especially in tuberculosis and intracellular infections [39].

➤ **Combination Therapies**

Combining fluoroquinolones with β -lactams, aminoglycosides, or efflux pump inhibitors is a growing strategy to enhance efficacy and delay resistance emergence.

These advances reflect ongoing innovation to preserve the clinical value of fluoroquinolones in the face of antimicrobial resistance [40].

FUTURE PERSPECTIVES

Despite the widespread utility of fluoroquinolones, increasing antimicrobial resistance and growing awareness of adverse effects underscore the need for innovation in this drug class [41-43]. Future development will rely on precision pharmacology, structure-guided drug design, and advanced delivery platforms to overcome current limitations.

Key research directions include:

- Designing next-generation fluoroquinolones with enhanced specificity for bacterial targets and reduced affinity for human topoisomerases to minimize toxicity.
- Developing novel derivatives that retain efficacy in acidic or intracellular environments, which is crucial for treating chronic and biofilm-associated infections.
- Employing computational modelling and AI-based screening to predict resistance mutations and guide the rational design of resistance-evading molecules.
- Exploring dual-targeting agents that effectively inhibit both DNA gyrase and topoisomerase IV with minimal cross-resistance.
- Advancing nanotechnology-based drug delivery systems to improve intracellular delivery, particularly for tuberculosis and other persistent infections.
- Enhancing synergistic combination regimens with β -lactams, efflux pump inhibitors, or antimicrobial peptides to restore activity against multidrug-resistant pathogens.

Equally important is the judicious clinical use of fluoroquinolones, guided by antimicrobial stewardship programs and genomic diagnostics, to preserve their efficacy [44-46]. In the long term, fluoroquinolones may serve not only as standalone antibiotics but also as scaffolds for multifunctional agents targeting emerging and resistant pathogens. Their continued evolution will be vital in addressing global infectious disease challenges.

CONCLUSION

Fluoroquinolones have revolutionized antibacterial therapy with their broad-spectrum activity, excellent pharmacokinetics, and versatility across various infections. Through successive generations and structural refinements, they have evolved to address diverse clinical needs, including respiratory, urinary, gastrointestinal, and even drug-resistant infections like multidrug-resistant tuberculosis. However, the emergence of resistance and reports of serious adverse effects have necessitated cautious and judicious use. Recent advances, including novel derivatives like delafloxacin and finafloxacin, nanotechnology-based delivery systems, and combination therapies, offer promising avenues to enhance efficacy and overcome current limitations. Continued innovation guided by structure–activity relationship insights,

pharmacodynamics, and resistance mechanisms will be crucial to sustain their therapeutic value. As we face a growing global burden of antimicrobial resistance, fluoroquinolones remain an essential tool—provided their use is balanced with careful monitoring, stewardship, and scientific advancement. Their legacy in antibacterial drug development highlights both their past success and future potential in combating infectious diseases.

REFERENCES

1. Aldred, K. J., Kerns, R. J., & Osheroff, N. (2014). Mechanism of quinolone action and resistance. *Biochemistry*, 53(9), 1565–1574.
2. Andriole, V. T. (Ed.). (2000). *The Quinolones* (3rd ed.). Academic Press.
3. Asif, M. (2015). Study of antimicrobial quinolones and structure–activity relationship of anti-tubercular compounds. *Research & Reviews: Journal of Chemistry*, 4, 28–70.
4. Baselt, R. (2008). *Disposition of toxic drugs and chemicals in man* (8th ed.). Biomedical Publications.
5. Bassetti, M., Righi, E., Pecori, D., & Tillotson, G. (2018). Delafloxacin: An improved fluoroquinolone developed through advanced molecular engineering. *Future Microbiology*, 13(10), 1081–1094.
6. Boswell, F. J., Andrews, J. M., Wise, R., & Dalhoff, A. (1999). Bactericidal properties of moxifloxacin and post-antibiotic effect. *Journal of Antimicrobial Chemotherapy*, 43(Suppl B), 43–49.
7. Brighty, K. E., & Gootz, T. D. (2000). Chemistry and mechanism of action of the quinolone antibacterials. In V. T. Andriole (Ed.), *The Quinolones* (pp. 33–97). Academic Press.
8. Bush, N. G., Diez-Santos, I., Abbott, L. R., & Maxwell, A. (2020). Quinolones: Mechanism, lethality and their contributions to antibiotic resistance. *Molecules*, 25(22), 5662.
9. Cottagnoud, P., Acosta, F., Cottagnoud, M., et al. (2002). Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis. *Antimicrobial Agents and Chemotherapy*, 46(6), 1607–1609.
10. Correia, S., Poeta, P., Hébraud, M., Capelo, J. L., & Igrejas, G. (2017). Mechanisms of quinolone action and resistance: Where do we stand? *Journal of Medical Microbiology*, 66(5), 551–559.
11. Coyle, E. A., & Rybak, M. J. (1999). Evaluation of the activity of the newer fluoroquinolones against ciprofloxacin-resistant *Streptococcus pneumoniae*. Abstract, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy.
12. Dalhoff, A., & Schmitz, F. J. (2003). In vitro antibacterial activity and pharmacodynamics of new quinolones. *European Journal of Clinical Microbiology & Infectious Diseases*, 22(4), 203–221.
13. Dejoies, L., & Cattoir, V. (2020). Fluoroquinolones: Classification, activités antibactériennes, résistances et indications thérapeutiques. *EMC – Maladies Infectieuses*, 37(1), 1–13.
14. Drusano, G. L. (1989). Pharmacokinetics of the quinolone antimicrobial agents. In J. S. Wolfson & D. C. Hooper (Eds.), *Quinolone antimicrobial agents* (pp. 71–105). American Society for Microbiology.
15. Eliopoulos, G. M., & Eliopoulos, C. T. (1989). Quinolone antimicrobial agents: Activity in vitro. In J. S. Wolfson & D. C. Hooper (Eds.), *Quinolone Antimicrobial Agents* (pp. 35–70). American Society for Microbiology.
16. Fish, D. N., & Chow, A. T. (1997). The clinical pharmacokinetics of levofloxacin. *Clinical Pharmacokinetics*, 32(2), 101–119.
17. Fish, D. N., & North, D. S. (2001). Gatifloxacin, an advanced 8-methoxy fluoroquinolone. *Pharmacotherapy*, 21(1), 35–59.
18. Forrest, A., Nix, D. E., Bellow, C. H., et al. (1992). Pharmacodynamics of IV

- ciprofloxacin in seriously ill patients. *Antimicrobial Agents and Chemotherapy*, 37(5), 1073–1081.
19. Firsov, A. A., et al. (2000). Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model. *Antimicrobial Agents and Chemotherapy*, 44(4), 879–884.
20. Garcia-Saenz, M. C., Puente-Arias, A., & Fresnadillo-Martinez, M. J., et al. (2001). Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin. *Journal of Cataract & Refractive Surgery*, 27(12), 1969–1974.
21. Gonzales, J., & Henwood, J. M. (1989). Pefloxacin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. *Drugs*, 37(4), 628–638.
22. Hajji, M., et al. (2018). Nephrotoxicity of ciprofloxacin: Five cases and a review of the literature. *Drug Safety Case Reports*, 5(1), 17.
23. Hooper, D. C. (2000). Mechanisms of action and resistance of older and newer fluoroquinolones. *Clinical Infectious Diseases*, 31(Suppl 2), S24–S28.
24. Hooper, D. C., & Jacoby, G. A. (2016). Topoisomerase inhibitors: Fluoroquinolone mechanisms of action and resistance. *Cold Spring Harbor Perspectives in Medicine*, 6(9), a025320.
25. Johnson, D. M., Cooper, M. A., Andrews, J. M., et al. (1992). Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. *Antimicrobial Agents and Chemotherapy*, 36(11), 2444–2446.
26. Kaplan, Y. C., & Koren, G. (2015). Use of ciprofloxacin during breastfeeding. *Canadian Family Physician*, 61(4), 343–344.
27. Kong, Y., Li, C., Li, G., Yang, T., Draz, M. S., Xie, X., Zhang, J., & Ruan, Z. (2022). In vitro activity of delafloxacin and finafloxacin against *Mycoplasma hominis* and *Ureaplasma* species. *Microbiology Spectrum*, 10, e00099-22.
28. Kunin, C. M. (1966). Clinical pharmacology of the new penicillins: Importance of serum protein binding. *Clinical Pharmacology & Therapeutics*, 7(2), 166–178.
29. Lees, P., & Shojaee Aliabadi, F. (2002). Rational dosing of antimicrobial drugs: Animals versus humans. *International Journal of Antimicrobial Agents*, 19(3), 269–284.
30. Leysen, D. C., Haemers, A., & Pattyn, S. R. (1989). Mycobacteria and the new quinolones. *Antimicrobial Agents and Chemotherapy*, 33(1), 1–5.
31. Lister, P. D., & Sanders, C. C. (1999). Pharmacodynamics of levofloxacin and ciprofloxacin against *Streptococcus pneumoniae*. *Journal of Antimicrobial Chemotherapy*, 43(1), 79–86.
32. Lode, H., Höfken, G., & Börner, K. (1998). Pharmacodynamics of fluoroquinolones. *Clinical Infectious Diseases*, 27(Suppl 1), S33–S39.
33. MacGowan, A. P., Bowker, K. E., Wootton, M., & Holt, H. A. (1999). Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for *Staphylococcus aureus* and streptococci. *Journal of Antimicrobial Chemotherapy*, 44(6), 761–766.
34. Maxwell, A., & Collin, F. (2011). Exploiting bacterial DNA gyrase as a drug target: Current state and perspectives. *Applied Microbiology and Biotechnology*, 92(3), 479–497.
35. Mogle, B. T., Steele, J. M., Thomas, S. J., Bohan, K. H., & Kufel, W. D. (2018). Clinical review of delafloxacin: A novel anionic fluoroquinolone. *Journal of Antimicrobial Chemotherapy*, 73(6), 1439–1451.
36. Munoz, M. J., et al. (1996). Pharmacokinetics of ciprofloxacin in sheep after single IV or IM administration. *Veterinary Quarterly*, 18(1), 45–48.
37. Noreddin, A. M., Haynes, V. L., & Zhanel, G. G. (2005). Pharmacokinetics and pharmacodynamics of the new quinolones. *International Journal of Clinical Practice*, 59(1), 13–25.
38. Odenholt, I., & Cars, O. (2006). Pharmacodynamics of moxifloxacin and levofloxacin against common pathogens. *Journal of Antimicrobial Chemotherapy*, 58(5), 960–965.
39. Remy, M., et al. (2018). Resistance selection experiments using delafloxacin against

- QRDR mutant *S. aureus*. Clinical Antimicrobial Resistance Reports.
40. Rodriguez-Rosado, M. P., et al. (2018). Mechanisms of fluoroquinolone-induced mutagenesis. *Antimicrobial Agents & Chemotherapy*, 62(2), e00000-18.
 41. Scott, L. J. (2020). Delafloxacin: A review in acute bacterial skin and skin structure infections. *Drugs*, 80(12), 1247–1258.
 42. Scott, S. N., et al. (2007). Roman's Quantum Effect on Fluoroquinolone Resistance. *Nature Medicine*, 13(5), 587–593.
 43. Saravolatz, L. D., & Stein, G. E. (2019). Delafloxacin: A new anti-methicillin-resistant *Staphylococcus aureus* fluoroquinolone. *Clinical Infectious Diseases*, 68(6), 1058–1062.
 44. Stass, H., Böttcher, M. F., & Ochmann, K. (2001). Influence of antacids on moxifloxacin absorption. *Clinical Pharmacokinetics*, 40(Suppl 1), 39–48.
 45. Vostrov, S. N., Kononenko, O. V., Lubenko, I. Y., Zinner, S. H., & Firsov, A. A. (2000). Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in vitro. *Antimicrobial Agents and Chemotherapy*, 44(4), 879–884.
 46. Jain, S. D., Prachand, S., Gupta, A. K., & Jain, S. (2023). Fluoroquinolones for the treatment of tuberculosis: An overview. *Asian Journal of Research in Pharmaceutical Sciences*, 13(4), 333–337.